Fundraising Fox
Spero
Cambridge, US · 3 known investors
Find your way into Spero
Sign up to find every way you can get introduced to Spero
- Your email: who you already know at Spero, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Spero team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps. The company's lead program, SP001, is a novel anti-CD40L monoclonal antibody being advanced in IgG4-related disease and other immune-related conditions.
Investors · 3
Atlas VenturereportedCambridge · $500K – $1M
How we know: funding news · Not right? Tell us
The Kraft GroupreportedFoxborough
How we know: funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Spero do?
- Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps. The company's lead program, SP001, is a novel anti-CD40L monoclonal antibody being advanced in IgG4-related disease and other immune-related conditions.
- Who are Spero's investors?
- Spero's investors include HEALTHCARE ROYALTY PARTNERS, Atlas Venture, The Kraft Group.
- Where is Spero headquartered?
- Spero is headquartered in Cambridge, US.